To determine whether antihypertensive therapy should be continued or discontinued in the acute situation.
- Antihypertensives Drug
Intervention Desc: This category includes all BP lowering drugs in stroke prevention trials
Multi-centre, prospective, randomised, open, blinded-endpoint study.
Patients will receive antihypertensive therapy for a 2-week period, after which administration will be at the discretion of individual clinicians. All routine aspects of patient management with respect to investigation, acute management and rehabilitation will be continued as standard local practice.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Primary outcome will be the mortality or dependent rate (Modified Rankin Score >2) at 14 days post-stroke.|
|Secondary||Early secondary outcome measures will include neurological and functional status, discharge destination and blood pressure levels (compared to admission) at 2 weeks. Late secondary outcome measures will include death and dependency, discharge destination and health-related quality of life at 6 months post-stroke.|